"Drug Design" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.
| Descriptor ID |
D015195
|
| MeSH Number(s) |
E05.295.500 H01.158.703.007.675.500 H01.181.466.675.500
|
| Concept/Terms |
Drug Design- Drug Design
- Design, Drug
- Designs, Drug
- Drug Designs
Drug Modeling- Drug Modeling
- Drug Modelings
- Modeling, Drug
- Modelings, Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Design".
Below are MeSH descriptors whose meaning is more specific than "Drug Design".
This graph shows the total number of publications written about "Drug Design" by people in this website by year, and whether "Drug Design" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 3 | 4 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Design" by people in Profiles.
-
1-Indanone and 1,3-indandione Derivatives as Ligands for Misfolded a-Synuclein Aggregates. ChemMedChem. 2022 01 19; 17(2):e202100611.
-
Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling. Eur J Med Chem. 2021 Apr 05; 215:113252.
-
Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer. Eur J Med Chem. 2021 Jan 01; 209:112866.
-
Design of a dual ERK5 kinase activation and autophosphorylation inhibitor to block cancer stem cell activity. Bioorg Med Chem Lett. 2020 Dec 01; 30(23):127552.
-
Rational design and development of a stable liquid formulation of riluzole and its pharmacokinetic evaluation after oral and IV administrations in rats. Eur J Pharm Sci. 2018 Dec 01; 125:1-10.
-
Expanding Benzoxazole-Based Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor Structure-Activity As Potential Antituberculosis Agents. J Med Chem. 2018 06 14; 61(11):4739-4756.
-
Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors. Bioorg Med Chem Lett. 2018 02 15; 28(4):577-583.
-
Preface. Curr Cancer Drug Targets. 2018; 18(1):2.
-
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016). Expert Opin Ther Pat. 2017 Jun; 27(6):677-690.
-
Selective Modulation of Protein Kinase C a over Protein Kinase C e by Curcumin and Its Derivatives in CHO-K1 Cells. Biochemistry. 2016 Apr 12; 55(14):2135-43.